FCM
AXSM icon

Frontier Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Frontier Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.3M Buy
203,066
+45,375
+29% +$7.84M 0.35% 99
2025
Q4 		$28.8M Buy
157,691
+31,309
+25% +$4.37M 0.31% 123
2025
Q3 		$15.3M Buy
126,382
+97,540
+338% +$11M 0.14% 211
2025
Q2 		$3.01M Sell
28,842
-14,419
-33% -$1.53M 0.03% 281
2025
Q1 		$5.05M Sell
43,261
-9,507
-18% -$1.08M 0.06% 254
2024
Q4 		$4.46M Sell
52,768
-67,772
-56% -$6.23M 0.04% 258
2024
Q3 		$10.8M Buy
120,540
+24,513
+26% +$2.14M 0.1% 209
2024
Q2 		$7.73M Sell
96,027
-9,317
-9% -$690K 0.08% 228
2024
Q1 		$8.41M Buy
105,344
+10,456
+11% +$878K 0.08% 225
2023
Q4 		$7.55M Sell
94,888
-65,788
-41% -$4.4M 0.08% 214
2023
Q3 		$11.2M Sell
160,676
-61,544
-28% -$4.6M 0.12% 183
2023
Q2 		$16M Buy
222,220
+181,515
+446% +$13.4M 0.15% 168
2023
Q1 		$2.51M Sell
40,705
-48,706
-54% -$3.2M 0.03% 247
2022
Q4 		$6.9M Buy
+89,411
New +$5.34M 0.08% 215

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Frontier Capital Management's AXSM Position: Q1 2026 in Review

Frontier Capital Management increased its Axsome Therapeutics (AXSM) stake by 29% in Q1 2026, buying an estimated $7.84M and bringing the position to 203,066 shares worth $34.3M. The position accounts for 0.35% of the portfolio, ranked #99.

Frontier Capital Management first reported a position in AXSM in Q4 2022 and has held it in 14 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Frontier Capital Management held 203,066 shares of Axsome Therapeutics worth $34.3M as of Q1 2026.
  • Frontier Capital Management bought 45,375 Axsome Therapeutics shares in Q1 2026, an estimated $7.84M.
  • Axsome Therapeutics made up 0.35% of Frontier Capital Management's portfolio in Q1 2026, its #99 holding.
  • Frontier Capital Management first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Frontier Capital Management's 13F filing for Q1 2026, filed 15 May 2026.